Answers are grounded in this paper and cite their sources.
A 67-year-old female taking Nivolumab for melanoma developed a hyperglycemic emergency requiring hospital admission. She was referred to our endocrinology clinic post-discharge where she was diagnosed with new-onset Type 1 diabetes mellitus. Severe hyperglycemia and immune-mediated diabetes mellitus are extremely rare but potentially life-threatening side effects of Nivolumab.
No takes yet. Share an insight, caveat, or question.
Baroud et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: